Revolutionizing Diabetes Treatment with Embrace Patch
Recent clinical trials have shed light on the embrace Active Site Care compression patch, a pioneering medical device that has demonstrated its efficacy in treating lipohypertrophy (LH) in individuals using insulin for diabetes management. This breakthrough reveals how comprehensive care and innovative technology can improve patient outcomes significantly.
Clinical Findings and Presentation
Neodyne Biosciences will soon present the results from a 16-week study showing how the embrace patch can lead to substantial improvements for those suffering from longstanding LH lesions. These findings mark a transformative moment for diabetes care, highlighting the importance of effective injection-site management in the overall treatment process.
Understanding Lipohypertrophy
Lipohypertrophy is a condition caused by repeated insulin injections, which can lead to increased adipose tissue and fibrosis at the injection sites. It affects approximately 64% of insulin users, making it a significant barrier to effective diabetes management. The complications of LH include variations in blood sugar levels and challenges in insulin absorption, which can complicate a patient’s condition.
Study Overview and Impact
The clinical trial involved 29 participants, each with at least two challenging LH lesions persisting for over five years. They applied the embrace patch to targeted lesions biweekly. The study found promising results, including a 20% reduction in lesion volume and a significant decrease in fibrotic tissue, showcasing the potential for the embrace patch to improve insulin delivery and overall patient satisfaction with therapy.
Patient Experience and Satisfaction
Feedback from participants has been overwhelmingly positive. Many noted that the embrace patch was not only easy to use but also helped them regain confidence in managing their diabetes by restoring the usability of previously affected injection sites. This kind of patient-centered approach is essential as it fosters a collaborative relationship between patients and healthcare providers.
First of its Kind in Diabetes Care
Kelley Lipman, president and CEO of Neodyne Biosciences, emphasized the significance of these findings. The embrace patch not only addresses the physical concerns of LH but also contributes to a more positive patient experience and better glycemic control. This innovative solution is set to change how healthcare professionals approach diabetes management.
Future Directions for Diabetes Management
The embrace poster, entitled "A Weekly Tension Offloading Patch for Lipohypertrophy", will be presented by Dr. Hans DeVries and Dr. Michael Longaker at the upcoming American Diabetes Association Science Sessions. This exposure will help inform more clinicians about the importance of LH management and the potential benefits of the embrace patch in their practice.
About Neodyne Biosciences
Founded at Stanford University, Neodyne Biosciences is on a mission to innovate and improve healthcare solutions through advanced technologies. Their embrace Active Site Care patch demonstrates a commitment to addressing significant yet often overlooked complications in diabetes care. The company is positioned at the forefront of medical technology, leveraging resources and expertise to develop effective therapies.
Frequently Asked Questions
What is lipohypertrophy and why is it a concern for insulin users?
Lipohypertrophy is a condition caused by repeated insulin injections leading to fat and scar tissue buildup, impacting insulin absorption and management of diabetes.
How does the embrace Active Site Care patch work?
The patch offloads tension on the skin and promotes the remodeling of adipose and fibrotic tissue, improving conditions at injection sites for insulin users.
What were the main findings of the clinical trial?
The trial found significant reductions in LH lesion volume and fibrosis, along with high patient satisfaction regarding ease of use and comfort.
Is the embrace patch cleared for medical use?
Yes, the embrace patch is 510(k) cleared and CE marked for use, making it accessible for immediate application at injection sites.
What future research or developments can we expect?
Further research will focus on expanding the use of the embrace technology and understanding its long-term benefits for diabetes management.
